title: Changes in serological biomarkers of liver function and connective tissue turnover in chronic hepatitis B during lamivudine therapy.
abstract: Assessment of hepatic damage associated with chronic hepatitis B (CHB) currently relies on measurement of serum transaminases and assessment of hepatic histology. It was determined serum hepatic function tests and the liver fibrosis biomarkers type IV collagen (CIV), amino-terminal propeptide of type I procollagen (PINP), amino-terminal propeptide of type III procollagen (PIIINP) and carboxy-terminal telopeptide of type I collagen (ICTP) were of value in monitoring the effect of lamivudine therapy for CHB. Thirty-nine patients received orally 100 mg lamivudine daily for 48 weeks. Blood samples were obtained at baseline, 24 and 48 weeks. At the end of the treatment period, the patients were then divided into four groups according to the pattern of HBs and HBe antigens. At baseline, alanine aminotransferase, aspartate aminotransferase, PIIINP and the PINP/ICTP ratio and at 24 weeks alanine aminotransferase, aspartate aminotransferase and the PINP/ICTP ratio had lower values in the complete response compared with complete failure groups. Using receiver-operated curve analysis, only the PINP/ICTP ratio at baseline (area under the curve 0.806) and ALT and the PINP/ICTP ratio at 24 weeks (areas under the curve 0.803 and 0.776, respectively) had significant diagnostic ability in detecting responders. In conclusion, the PINP/ITCP ratio is sensitive and specific in detecting responders to treatment.
authors.affiliation: Biochemistry Department, Stobhill Hospital, Glasgow, UK. paul.maxwell@northglasgow.scot.nhs.uk
authors.forename: P R
authors.initials: PR
authors.lastname: Maxwell
authors.forename: R
authors.initials: R
authors.lastname: Flisiak
mesh_terms: D000328:Adult; D019540:Area Under Curve; D015415:Biomarkers; D003238:Connective Tissue / Q000378:metabolism*; D016326:Extracellular Matrix Proteins / Q000378:metabolism; D005260:Female; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008099:Liver / Q000473:pathology; D008103:Liver Cirrhosis / Q000378:metabolism / Q000473:pathology; D008111:Liver Function Tests; D008297:Male; D012372:ROC Curve; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*
chemical_list: D015415:Biomarkers; D016326:Extracellular Matrix Proteins; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine